

1 **Absolute quantification of uric acid in human urine using surface enhanced Raman**
2 **scattering and standard addition method**

3

4 Chloe Westley^a, Yun Xu^a, Baskaran Thilaganathan^b, Andrew J. Carnell^c, Nicholas J. Turner^a,
5 Royston Goodacre^{a*}

6 ^a School of Chemistry, Manchester Institute of Biotechnology, University of Manchester, 131
7 Princess Street, Manchester, M1 7DN, UK.

8 ^bSt George's, University of London & St George's University Hospitals NHS Foundation
9 Trust Clinical Sciences Research Centre, London, SW17 0RE

10 ^cDepartment of Chemistry, University of Liverpool, Liverpool, L69 7ZD

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29 **ABSTRACT**

30

31 High levels of uric acid in urine and serum can be indicative of hypertension, and the
32 pregnancy related condition, preeclampsia. We have developed a simple, cost-effective,
33 portable surface enhanced Raman scattering (SERS) approach for the routine analysis of uric
34 acid at clinically relevant levels in urine patient samples. This approach, combined with
35 standard additions method (SAM), allows for the absolute quantification of uric acid directly
36 in a complex matrix such as that from human urine. Results are highly comparable and in
37 very good agreement with HPLC results, with an average <9% difference in predictions
38 between the two analytical approaches across all samples analysed, with SERS demonstrating
39 a 60-fold reduction in acquisition time compared with HPLC. For the first time, clinical pre-
40 preeclampsia patient samples have been used for quantitative uric acid detection using a
41 simple, rapid colloidal SERS approach without the need for complex data analysis.

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60 INTRODUCTION

61

62 Preeclampsia is a hypertension disorder that can occur in pregnant women and is a primary
63 cause for maternal morbidity and mortality worldwide, mainly in developing countries, with
64 2-5% of pregnancies affected.¹⁻³ The cause of preeclampsia remains unknown and even
65 predicting which women are susceptible/have an increased risk of developing the condition is
66 problematic.^{4,5} Moreover, when preeclampsia appears in the second or third trimester, there
67 are no treatments available other than premature delivery of the baby,⁶ and those babies born
68 are exposed to an increased risk of developing hypertension, heart disease and diabetes^{1,7,8}.
69 Currently, diagnosis of preeclampsia is a challenge as it relies on non-specific signs of the
70 disease⁹; commonly associated symptoms include raised blood pressure and elevated protein
71 levels (proteinuria) in the urine and so blood tests and urine protein measurement tests are
72 often performed.¹⁰

73 Uric acid has been identified as an important biomarker for various diseases such as
74 cardiovascular diseases, gout, renal diseases and preeclampsia.¹¹⁻¹⁵ Uric acid is the end
75 product of the metabolic breakdown of purine nucleotides and in normal circumstances,
76 concentrations range from 3.5-7.0 mg/dL in the blood and from 16-100 mg/dL per 24 h in
77 urine.¹⁶ Moreover, elevated uric acid levels (referred to as hyperuricemia) in urine and serum
78 has been associated with preeclampsia, with levels greater than 0.4 mM indicating severe
79 preeclampsia.¹⁷

80 Colorimetric enzymatic assays, liquid chromatography and capillary electrophoresis
81 methodologies have been reported for uric acid detection; however, associated disadvantages
82 include that these tests are often only applicable to late-stage preeclampsia, involve time
83 consuming assay based tests, expensive enzymes, sophisticated instrumentation and
84 equipment and often lack sensitivity. Therefore, there is a great need for a rapid, inexpensive,
85 routine, diagnostic test to aid early uric acid detection, thus allowing hyperuricemia
86 conditions to be properly monitored and managed to prevent further health implications.^{18,19}

87 Surface enhanced Raman scattering (SERS) has increasingly been employed for use in
88 quantification of biologically relevant molecules²⁰⁻²⁴. SERS is the dramatic enhancement of
89 Raman signals when an analyte is in close proximity/absorbed onto a nanoscale rough
90 metallic surface, with typical enhancements of 10^4 - 10^6 observed. It is an attractive approach
91 for disease diagnosis as it yields molecular specific information, is label-free, has the ability
92 to be performed in aqueous environments and has high sensitivity with low analyte
93 concentration detection (down to fM level and single molecule detection).²⁵⁻²⁸

94 Raman spectroscopy also offers several advantages including its ease-of-use along with
95 portability²⁹ leading to the ability to develop point-of-care analysis systems for on-site Point-
96 and-Shoot analyses.³⁰ Recently, there have been several Raman spectroscopy based
97 approaches, mostly utilising electrochemical surface enhanced Raman (E-SERS), to measure
98 uric acid detection. However, these studies have demonstrated problems in establishing
99 reliable, quantitative detection of uric acid at clinically relevant concentrations³¹, have

100 employed complex sample make up^{32,33} and used complex data analysis³⁴. In all cases, the
101 studies were not performed in real-life situations, i.e. biological fluids, but instead were
102 performed in either urine stimulant, synthetic urine or water.³⁵

103

104 In this paper, we present an optimised SERS approach for uric acid detection in human urine
105 from clinical pre-preeclamptic patients (urine samples collected between 11-14 weeks
106 gestation) using a portable, easy-to-use Raman instrument. As uric acid is already present in
107 urine, our approach involves using the well-known standard additions method (SAM), as well
108 as HPLC analysis for additional benchmarking (see **supporting information Figure S1**). In
109 SAM, a series of samples are analysed involving spiking in known amounts of uric acid in
110 increasing concentrations whereby the subsequent calibration curve is used to determine the
111 unknown concentration of uric acid in the original (undiluted) sample. We have performed
112 this approach on 21 clinical samples, of which, 11 were performed in triplicate analysis to
113 establish reproducibility, affording direct quantification of the target analyte within the
114 sample thus accounting for the complex sample matrix. To the best of our knowledge, this
115 simple colloidal uric acid detection approach in clinical patient samples is the first study of its
116 kind.

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132 RESULTS AND DISCUSSION

133

134 SERS optimisation

135

136 We have previously established optimised conditions for uric acid SERS detection within an
137 enzymatic system by varying certain parameters such as colloid type, pH, concentration, time
138 aggregation and aggregating agent.⁸ However, uric acid detection in a more complex matrix,
139 such as urine which is a molecular milieu of small molecules, organic acids and ions as well
140 as proteins, required a slightly different set of conditions. Optimised conditions were
141 established using a pooled QC urine sample (from all 58 patient samples), and as before
142 hydroxylamine-reduced silver colloid was the optimum SERS substrate to use, at pH 7.6,
143 without the need for an aggregating agent. The aggregation time was slightly modified, with
144 optimum uric acid detection achieved after 3.5 min (\pm 1 min) aggregation (see **Figure 1** and
145 **supporting information Figures S2 and S3**). **Table 1** shows the tentative SERS band
146 assignments for uric acid (see **supporting information Figure S4** for normal Raman spectra
147 of uric acid (solid) which aided in band assignment).^{8,13,35}

148

149

150

151

152


153

154

155

156

157



158 **Figure 1** Annotated mean averaged SERS spectra ($n = 5$) of uric acid. SERS spectra were
159 obtained for 20 s, at 25 μ M (dissolved in water) using 200 μ L of hydroxylamine reduced
160 silver colloid, potassium phosphate buffer at pH 7.6; measurements were made 3 min after
aggregation.

158

159

160

161 **Table 1:** Band assignments for normal Raman (solid) and tentative SERS (25 μM solution)
band assignments for the Uric Acid

Raman Shift (cm^{-1})	SERS Peak (cm^{-1})	Tentative band assignment ^[8,13,35]
380 (mw)	-	-
-	508 (vwsh)	C-N-C ring vibrations
-	534 (vw)	
626 (w)	640 (s)	Skeletal ring deformation
705 (w)	730 (w)	N-H bending
783 (m)	812 (m)	Ring vibration
884 (w)	889 (m)	N-H bending
998 (s)	1017 (w)	Ring vibrations
1033 (vs)	-	-
1122 (s)	1134 (vs)	C-N
1233 (s)	1206 (m)	N-C-C stretching and bending
1289 (s)	1266 (w)	-
1355 (w)	1369 (s)	C-O
-	1515 (vwsh)	Asymmetric deformation NH_3
1406 (vs)	-	-
1499 (s)	-	-
1596 (m)	1554 (m)	C-N
1679 (vs)	1684 (s)	-

162

163 v –stretching, b-bending, R-ring; trigd-trigonal deformation, s-strong, vs-very strong, m-medium,
w-weak, vw-very weak

164

165 A concern for the analysis in human urine was the effect the pH of individual samples would
166 have on the SERS spectrum as well as any potential difference in how the target analyte
167 would interact with the silver surface. After dilution, the pH of the urine samples varied
168 considerably from 4.45 – 9.3, meaning uric acid would be in different ionisation states and
169 consequently interact with the surface differently, generating sub-optimal SERS spectra,
170 ultimately not representing the actual concentration in the sample. To overcome this and to
171 ensure the urine sample had an overall pH that coincided with optimal uric acid detection, the
172 sample environment was carefully modified. A potassium phosphate buffer at pH 7.6 was
173 added to the colloid and urine, as well as the uric acid spiked in to the sample for the standard
174 additions measurements. Therefore, after all constituents were added (i.e. urine, buffer,
175 spiked uric acid and colloid), the overall sample pH for all patients varied from pH 7.2 – 8.

176 This meant that in all analyses uric acid was predominantly in its negative 1 ionisation state
177 and would have the same affinity for the colloidal surface thus affording more reproducible
178 and optimal SERS uric acid detection for all samples (see **supporting information Figure**

179 **S3**). Moreover, the presence of additional buffer (i.e. 75 μL) in the sample make up was
180 necessary as it also acted as an aggregating agent to help stabilise the SERS response,
181 especially for samples where low uric acid (or none, as in the blank) was spiked in.

182

183 **Standard additions method (SAM) approach**

184

185 Previously for quantifying uric acid within a mixture (in terms of monitoring
186 biotransformation(s) involving three analytes) we used various chemometric approaches such
187 as partial least squares regression (PLSR) and multivariate curve resolution-alternating least
188 squares (MCR-ALS).⁸ However, these data analysis methods are not suitable for quantifying
189 analytes in complex matrices where the sample matrix actually contributes to the analytical
190 signal (i.e., when uric acid is already present in urine). Standard additions method (SAM)
191 works by spiking in known amounts of standard, in this case uric acid, and plotting peak area
192 (of a characteristic peak, *viz.* 1134 cm^{-1}) against the concentration of the standard spiked in,
193 thus yielding a straight line ($y = mx + b$; where m and b are the slope of the line and
194 y -intercept, respectively). From there, the concentration of the analyte can be determined
195 from the point at which the extrapolated line crosses the concentration axis (x) at zero signal
196 (i.e. where $y = 0$ and thus $x = -b/m$ such that the concentration = b/m).^{36,37}

197 A prerequisite in order to use SAM is a linear relationship between the concentration and the
198 SERS signal of uric acid. From performing a concentration profile (see **supporting**
199 **information Figure S2a**), the linear concentration range was determined to be between 1 –
200 100 μM). Therefore, for some samples, dilution of the initial urine sample was performed to
201 ensure that on spiking in a known amount of standard, this linear concentration range was
202 retained. Notably, in cases of saturation, comparably lower SERS signals are observed for
203 higher analyte concentrations, as seen beyond 100 μM , and a non-linear relationship is
204 observed. We also had to consider the effect of the concentration-dependence on the
205 orientation of the target molecule on the colloidal surface. We noticed that below 5 μM ,
206 although still part of the linear relationship, the SERS spectrum of uric acid changed slightly,
207 in terms of intensity and broadness of certain peaks, indicating the orientation of the analyte
208 molecule on the surface was probably different. Therefore, for this reason, 5 - 100 μM was
209 determined to be the optimum total concentration range of uric acid in the urine sample,
210 taking into account spiking of standard and dilution factors.

211

212 **Sample selection and SAM Analysis**

213

214 Rather than measure all samples, 21 samples from the 58 human urine samples were
215 randomly selected for comparative SERS and HPLC SAM analysis – we ensured that the
216 samples selected covered the entire uric acid concentration range. The characteristic peak for

217 uric acid used in the analysis was at 1134 cm^{-1} , corresponding to the C-N vibration. **Table 2**
 218 shows a summary of the results from each analytical approach along with the associated
 219 percentage differences. As an example, for sample 18, HPLC results predicted a uric acid
 220 concentration of $172\text{ }\mu\text{M}$, compared to $186\text{ }\mu\text{M}$ predicted from SERS, a difference of 7.5%.
 221 Overall, for all samples analysed, the percentage difference between the two analytical
 222 approaches ranged from 0.8% (sample 20) to 19.1% (sample 40), with the average percentage
 223 difference being 8.4%. This is very encouraging considering the uric acid concentration
 224 range was extensive (starting from around $65\text{ }\mu\text{M}$ to $670\text{ }\mu\text{M}$) meaning this approach could
 225 be extended to target other uric acid related diseases (i.e. those related to *low* concentration of
 226 uric acid (hypouricemia) as well as elevated uric acid levels (hyperuricemia) such as in
 227 preeclampsia).

228

229 **Table 2:** Summary of results for all samples analysed: HPLC (μM), SERS (μM) and the
 230 associated percentage differences between the two analytical approaches

Sample	HPLC (μM)	SERS (μM)	Difference	Sample	HPLC (μM)	SERS (μM)	Difference
QC (n=58)	190.3	181.1	4.8%	26	215.0	182.9	14.9%
1	274.9	266.6	3.1%	31	548.5	601.6	8.8%
4	112.9	111.8	1.0%	36	206.9	187.7	10.2%
5	119.4	135.1	11.6%	40	219.2	184.0	19.1%
9	64.5	73.2	11.9%	41	309.8	294.2	5.3%
12	91.5	88.4	3.4%	44	196.6	188.7	4.0%
14	70.1	73.1	4.1%	47	183.0	157.5	16.2%
16	511.2	561.6	9.9%	49	679.4	665.5	2.1%
18	172.0	186.0	7.5%	52	249.5	233.8	6.7%
20	151.9	153.1	0.8%	53	126.3	117.4	7.1%
22	234.6	199.3	15.0%	55	345.8	301.6	12.8%

231

232 NB Dilution factors taken into account. See ‘Preparation of urine for HPLC and SERS analysis’ in Supporting
 233 Information.

234

235 We next wanted to address the reproducibility of this SERS approach. Eleven of the 21
 236 samples were randomly selected for triplicate HPLC and SERS analysis. For the latter, this
 237 meant using a different colloidal batch for each replicate performed (see **supporting**
 238 **information Figure S5**). In general, batch-to-batch variation and reproducibility of SERS
 239 enhancements is a key discussion point within the Raman community.³⁸⁻⁴¹ Groups report
 240 noticeable discrepancies in results due to variations in colloidal batches, colloid
 241 concentrations and nanoparticle aggregation – all of which can result in inconsistent
 242 enhancements. However, we have demonstrated using these optimised set of conditions for
 243 uric acid detection in urine that we can produce consistent, reliable results that are in good

244 agreement and comparable to HPLC results, the ‘gold standard’ in this case and used for
245 benchmarking (see **Table 3**).

246 As an example, sample 20 was subjected to triplicate analysis (see **supporting information**
247 **Figure S6**). The average percentage difference between the HPLC and SERS results was just
248 over 1.5% across the three replicates. The standard deviation (SD) for SERS results was 4.1
249 (compared to 3.3 for HPLC) and the relative standard deviations (RSD) were 2.1 and 2.7%
250 for HPLC and SERS respectively. These results are excellent in terms of accuracy (difference
251 between HPLC and SERS), precision (SD for these repeat measurements) and overall
252 reproducibility. To emphasise this further, the average percentage difference for triplicate
253 analysis between the two analytical approaches was 7.2%, with the average SD and RSD for
254 SERS being 12.8 and 6.7% and for HPLC, 6.3 and 3.3% respectively.

255

256 **Table 3:** Summary of results for samples involving triplicate analysis including associated
257 percentage differences between the two analytical approaches, standard deviations (SD)
and relative standard deviations (RSD)

Sample	HPLC (µM)	SD (±)	RSD (±)	SERS (µM)	SD (±)	RSD (±)	Difference
1	274.9	13.6	5.0%	266.6	17.4	6.5%	3.1%
4	112.9	3.8	3.4%	111.8	9.6	8.6%	1.0%
5	119.4	1.5	1.3%	135.1	11.1	8.3%	11.6%
12	91.5	6.0	6.5%	88.4	9.2	10.5%	3.4%
20	152.3	3.2	2.1%	153.1	4.1	2.7%	1.5%
36	206.9	5.0	2.4%	187.7	8.4	4.5%	10.2%
40	219.2	1.6	0.7%	184.0	12.5	6.8%	19.1%
41	309.8	10.8	3.5%	294.2	16.8	5.7%	5.3%
47	183.0	6.1	3.3%	157.5	13.4	8.5%	16.2%
49	679.4	9.4	4.2%	665.5	16.5	2.5%	2.1%
52	249.5	8.5	3.4%	233.8	22.1	9.4%	6.7%
Control*	51.0	0.7	1.4%	53.9	4.6	8.5%	7.8%

258

259 *Control is to establish overall errors associated with each technique. 50 µM (i.e. known concentration) was
spiked into blank

260 The average difference between the two analytical approaches was 7.2%. The average SD and RSD for SERS
261 was 12.8 and 6.7% and for HPLC, 6.3 and 3.3% respectively.

262 To confirm further how excellent the agreement of data are between the two analytical
263 approaches, **Figure 2a**) shows a HPLC *versus* SERS plot for all 21 analyses, reflecting a very
264 good linear trend with an R^2 of 0.9792. In addition, **Figure 2b**) is a plot of percentage
265 difference (from HPLC – SERS predictions) against HPLC predicted concentration for all
266 samples analysed. The ‘randomness’ of the plot (i.e. both positive and negative differences)
267 indicates that there is no systematic bias in the analysis. Notably, there are less samples
268 analysed at high uric acid levels, and ideally we would want an even spread of samples across

269 the entire uric acid concentration range to demonstrate fully how applicable this SERS
270 approach is. However, these samples are real, clinical pre-preeclampsia samples and hence
271 this is reflected by the uric acid concentrations observe

272

273

274


275

276

277

278

279



280 **Figure 2 a)** A plot of predictions from HPLC vs. SERS for all samples (including replicates)
281 with an R^2 of 0.9792 indicating results are in very good agreement. **b)** A plot of percentage
282 difference (from HPLC – SERS predictions) against HPLC predicted concentration for all
283 samples analysed, indicating that there is no systematic bias in the analysis.

283

284 Noticeably, SERS results have slightly higher SD and RSD throughout the samples analysed.
285 However, the reduction in acquisition times for SERS analysis largely compensates and
286 outweighs this. In total, SAM HPLC takes 140 min (7 samples \times 20 min HPLC trace) for uric
287 acid prediction for each sample. Comparatively, SAM SERS analysis takes 140 s (7 samples
288 \times 20 s SERS acquisition), a 60-fold reduction and yet results are in very good agreement and
289 highly comparable. There is only on average 8.4% difference for all samples analysed. There
290 was on average 7.2% difference for the triplicate analysis indicating that the precision and
291 accuracy were similar. Moreover, if one considers the actual associated error with each
292 analytical approach (see **Table 2**) - for HPLC there are associated SD and RSD of 0.7 and
293 1.4% and for SERS 4.6 and 8.5% respectively - there is overlap and leeway in the results
294 between the two analytical approaches, making this SERS approach a highly attractive
295 alternative that could be used in clinical settings. Finally on this point, the cost of the analysis
296 is comparable, as HPLC apparatus include instrument costs and consumables, which are
297 equivalent to low-cost portable and indeed hand-held Raman spectrometers plus cost of
298 colloid and reagents.

299

300

301

302 ONLINE METHODS

303 Full experimental details are provided in the **supporting information** ‘Supplementary
304 Methods’ section.

305 **Materials.** All chemical reagents were of analytical grade and used with no additional
306 purification unless otherwise stated.

307 **Human urine samples** were kindly donated by Prof B. Thilaganathan from St George’s,
308 University of London & St George’s University Hospitals NHS Foundation Trust Clinical
309 Sciences Research Centre. Written informed consent was obtained from each study
310 participant and the study conformed to the principles set out in the WMA Declaration of
311 Helsinki and the NIH Belmont report. The study was approved by Wandsworth Local
312 Research Ethics Committee.

313 **Processing of Urine.** For optimisation of uric acid detection in urine, we used a pooled urine
314 stock from 58 different patients (QC $n=58$). For each urine sample, a protein crash method
315 was performed using methanol (at RT). 150 μL urine was aliquoted in Eppendorf tubes. 600
316 μL methanol was added to this, and centrifuged for 15 min at $13,500 \times g$. 400 μL was
317 removed from the supernatant into a new Eppendorf tube and concentrated for ~ 4 h using an
318 Eppendorf Vacufuge Concentrator 5301 (Eppendorf, UK). Once all methanol had been
319 removed, the sample was re-suspended in 150 μL water and vortexed for 5 s.

320 **Sample Selection.** All urine samples from the 58 patients were processed as described above.
321 For the QC sample used in optimising various parameters for SERS detection, all 58 urine
322 samples were pooled. 21 of these 58 urine samples were randomly selected to cover the entire
323 uric acid concentration range to remove any measurement redundancy. Triplicate analyses
324 were then performed on 11 of these 21 samples to establish reproducibility.

325 **Sample preparation.** 3.5×10^{-4} M uric acid stock solution was prepared in 1M potassium
326 phosphate buffer solution at pH 7.6. Samples for individual analyses were then prepared as
327 follows: For SERS samples, 200 μL of hydroxylamine reduced Ag colloid (HRSC), 75 μL
328 potassium phosphate buffer at pH 7.6 and 125 μL urine was added to a glass vial. The silver
329 colloid was prepared according to the method of Leopold and Lendl.⁴² For HPLC samples,
330 the same procedure was followed except water was added instead of colloid. For SAM
331 sample preparation the concentration of uric acid spiked into each urine sample was 0, 8.5,
332 16.7, 24.4, 31.8, 38.9, 45.7 and 55.3 μM . All dilution factors were taken into account when
333 predicting final uric acid concentrations.

334 **Raman Instrumentation.** A DeltaNu Advantage 200A portable Raman spectrometer
335 (DeltaNu, Laramie, WY, USA) was used for collection of spectra using a HeNe 633 nm laser
336 with ~ 3 mW on the sample.

337 **CONCLUSION**

338

339 There is a real urgent unmet need for early diagnosis of preeclampsia in pregnant women. We
340 have demonstrated a SERS based approach to measure uric acid in pre-preeclamptic urine
341 samples which yields absolute quantitation. In combination with the well-known SAM
342 approach, uric acid concentrations have been predicted in urine samples from 21 different
343 patients, and benchmarked against HPLC. It is highly notable that there is a 60-fold reduction
344 in acquisition time when employing this SERS-based approach, and yet the average
345 difference between the two analytical approaches is less than 9%. Furthermore, we have
346 demonstrated excellent reproducibility, with 11 of these samples performed in triplicate
347 analysis using different colloidal batches (for each replicate) highlighting its use for
348 applications in rapid, routine detection of uric acid. We believe this new SERS-SAM
349 analytical approach could easily be translated into an on-site, diagnostic tool for early
350 diagnosis of preeclampsia and indeed other disease where quantification of uric acid is
351 needed.

352

353

354

355 **ACKNOWLEDGEMENTS**

356

357 CW is grateful to BBSRC for a PhD studentship. We are very grateful to Professor Ray K
358 Iles for helping source human urine samples and St George's, University of London & St
359 George's University Hospitals NHS Foundation Trust Clinical Sciences Research Centre. YX
360 thanks the Cancer Research UK for funding (including an Experimental Cancer Medicine
361 Centre award). AJC would like to acknowledge BBSRC for funding (BB/M028631/1). NJT
362 and RG are also indebted to BBSRC and GSK for financial funding (grant BB/K00199X/1).
363 NJT thanks the Royal Society for a Wolfson Research Merit Award.

364

365

366

367

368

369

370

371

372

373

374

375 **REFERENCES**

376

- 377 1 Kenny, L. C. *et al.* Detection and identification of novel metabolomic biomarkers in
378 preeclampsia. *Reproductive sciences (Thousand Oaks, Calif.)* **15**, 591-597 (2008).
- 379 2 Goldenberg, R. L., McClure, E. M., Macguire, E. R., Kamath, B. D. & Jobe, A. H.
380 Lessons for low-income regions following the reduction in hypertension-related
381 maternal mortality in high-income countries. *Int J Gynecol Obstet* **113**, 91-95 (2011).
- 382 3 Conde-Agudelo, A., Belizan, J. M. & Lammers, C. Maternal-perinatal morbidity and
383 mortality associated with adolescent pregnancy in Latin America: Cross-sectional
384 study. *Am. J. obstet gynecol* **192**, 342-349 (2005).
- 385 4 Carty, D. M., Delles, C. & Dominiczak, A. F. Novel biomarkers for predicting
386 preeclampsia. *Trends cardiovas med* **18**, 186-194 (2008).
- 387 5 Johnson, J. A. Advancing management of hypertension through pharmacogenomics.
388 *Ann med* **44**, 17-22 (2012).
- 389 6 Redman, C. W. & Sargent, I. L. Latest Advances in Understanding Preeclampsia.
390 *Science* **308**, 1592-1594 (2005).
- 391 7 Barker, D. J. *et al.* Fetal nutrition and cardiovascular disease in adult life. *Lancet* **341**,
392 938-941 (1993).
- 393 8 Westley, C., Xu, Y., Carnell, A. J., Turner, N. J. & Goodacre, R. Label-Free Surface
394 Enhanced Raman Scattering Approach for High-Throughput Screening of
395 Biocatalysts. *Anal chem* **88**, 5898-5903 (2016).
- 396 9 Kar, M. Role of Biomarkers in Early Detection of Preeclampsia. *J Clin Diagn Res* **8**,
397 BE01-BE04 (2014).
- 398 10 Roberts, J. M. & Cooper, D. W. Pathogenesis and genetics of pre-eclampsia. *Lancet*
399 **357**, 53-56 (2001).
- 400 11 Bainbridge, S. A. & Roberts, J. M. Uric Acid as a Pathogenic Factor in Preeclampsia.
401 *Placenta* **29**, S67-S72 (2008).
- 402 12 Feig, D. I., Kang, D.-H. & Johnson, R. J. Uric Acid and Cardiovascular Risk. *N*
403 *Engl J Med* **359**, 1811-1821 (2008).
- 404 13 Kodati, V. R., Tu, A. T. & Turumin, J. L. Raman Spectroscopic Identification of Uric-
405 Acid-Type Kidney Stone. *Appl. spectrosc* **44**, 1134-1136 (1990).
- 406 14 Puig, J. *et al.* Serum urate, metabolic syndrome, and cardiovascular risk factors. A
407 population-based study. *Nucleos Nucleot Nucl* **27**, 620-623 (2008).
- 408 15 Roberts, J. M. & Gammill, H. S. Preeclampsia recent insights. *Hypertension* **46**, 1243-
409 1249 (2005).
- 410 16 Feig, D. I. *et al.* Serum uric acid: a risk factor and a target for treatment? *J Am Soc*
411 *Nephrol* **17**, S69-73 (2006).
- 412 17 Buhimschi, C. S. *et al.* Urinary angiogenic factors cluster hypertensive disorders and
413 identify women with severe preeclampsia. *Am. J. obstet gynecol* **192**, 734-741 (2005).
- 414 18 Mikat, B. *et al.* Early detection of maternal risk for preeclampsia. *ISRN obstet gynecol*
415 **2012** 1-7 (2012).
- 416 19 Rasanen, J. *et al.* Maternal serum glycosylated fibronectin as a point-of-care
417 biomarker for assessment of preeclampsia. *Am. J. obstet gynecol* **212**, 82.e81-82.e89
418 (2015).
- 419 20 Ma, K. *et al.* In Vivo, Transcutaneous Glucose Sensing Using Surface-Enhanced
420 Spatially Offset Raman Spectroscopy: Multiple Rats, Improved Hypoglycemic
421 Accuracy, Low Incident Power, and Continuous Monitoring for Greater than 17 Days.
422 *Anal chem* **83**, 9146-9152 (2011).

- 423 21 Zhang, D. *et al.* Ultrasensitive detection of malondialdehyde with surface-enhanced
424 Raman spectroscopy. *Anal bioanal chem* **398**, 3193-3201 (2010).
- 425 22 Alharbi, O., Xu, Y. & Goodacre, R. Simultaneous multiplexed quantification of
426 caffeine and its major metabolites theobromine and paraxanthine using surface-
427 enhanced Raman scattering. *Anal bioanal chem* **407**, 8253-8261(2015).
- 428 23 Cialla, D., Pollok, S., Steinbrücker, C., Weber, K. & Popp, J. SERS-based detection
429 of biomolecules. *Nanophotonics* **3**, 383-411 (2014).
- 430 24 Sorensen, K. M., Westley, C., Goodacre, R. & Engelsen, S. B. Simultaneous
431 quantification of the boar-taint compounds skatole and androstenone by surface-
432 enhanced Raman scattering (SERS) and multivariate data analysis. *Anal bioanal chem*
433 **407**, 7787-7795 (2015).
- 434 25 Haes, A. J. *et al.* Plasmonic Materials for Surface-Enhanced Sensing and
435 Spectroscopy. *MRS Bulletin* **30**, 368-375 (2005).
- 436 26 Smith, W. E. Practical understanding and use of surface enhanced Raman
437 scattering/surface enhanced resonance Raman scattering in chemical and biological
438 analysis. *Chem Soc Rev* **37**, 955-964 (2008).
- 439 27 Kneipp, K. *et al.* Single molecule detection using surface-enhanced Raman scattering
440 (SERS). *Phys Rev Lett* **78**, 1667 (1997).
- 441 28 Yang, S., Dai, X., Stogin, B. B. & Wong, T.-S. Ultrasensitive surface-enhanced
442 Raman scattering detection in common fluids. *Proc. Natl. Acad. Sci. U.S.A.* **113**, 268-
443 273 (2016).
- 444 29 Cowcher, D. P., Xu, Y. & Goodacre, R. Portable, quantitative detection of *Bacillus*
445 bacterial spores using surface-enhanced Raman scattering. *Anal chem* **85**, 3297-3302,
446 (2013).
- 447 30 Ellis, D. I., Muhamadali, H., Haughey, S. A., Elliott, C. T. & Goodacre, R. Point-and-
448 shoot: rapid quantitative detection methods for on-site food fraud analysis—moving
449 out of the laboratory and into the food supply chain. *Anal. Methods* **7**, 9401-9414
450 (2015).
- 451 31 Pucetaite, M. *et al.* Uric acid detection by means of SERS spectroscopy on dried Ag
452 colloidal drops. *J Raman Spectrosc* **47**, 681-686, (2016).
- 453 32 Kammer, E. *et al.* Quantitative SERS studies by combining LOC-SERS with the
454 standard addition method. *Anal bioanal chem* **407**, 8925-8929 (2015).
- 455 33 Zhao, L., Blackburn, J. & Brosseau, C. L. Quantitative Detection of Uric Acid by
456 Electrochemical-Surface Enhanced Raman Spectroscopy Using a Multilayered Au/Ag
457 Substrate. *Anal chem* **87**, 441-447 (2015).
- 458 34 Villa, J. E. L. & Poppi, R. J. A portable SERS method for the determination of uric
459 acid using a paper-based substrate and multivariate curve resolution. *Analyst* **141**,
460 1966-1972, (2016).
- 461 35 Goodall, B. L., Robinson, A. M. & Brosseau, C. L. Electrochemical-surface enhanced
462 Raman spectroscopy (E-SERS) of uric acid: a potential rapid diagnostic method for
463 early preeclampsia detection. *Phys Chem Chem Phys* **15**, 1382-1388 (2013).
- 464 36 Bruce, G. R. & Gill, P. S. Estimates of Precision in a Standard Additions Analysis. *J*
465 *Chem Edu* **76**, 805 (1999).
- 466 37 Stark, T., Wollmann, N., Losch, S. & Hofmann, T. Quantitation of resveratrol in red
467 wines by means of stable isotope dilution analysis-ultra-performance liquid
468 chromatography-Quant-time-of-flight mass spectrometry and cross validation. *Anal*
469 *chem* **83**, 3398-3405 (2011).
- 470 38 Larmour, I. A., Faulds, K. & Graham, D. SERS activity and stability of the most
471 frequently used silver colloids. *J Raman Spectrosc* **43**, 202-206 (2012).

- 472 39 Yaffe, N. R. & Blanch, E. W. Effects and anomalies that can occur in SERS spectra of
473 biological molecules when using a wide range of aggregating agents for
474 hydroxylamine-reduced and citrate-reduced silver colloids. *Vib. Spectrosc* **48**, 196-
475 201 (2008).
- 476 40 Hobro, A. J., Jabeen, S., Chowdhry, B. Z. & Blanch, E. W. Time Dependence of
477 SERS Enhancement for Pyrimidine Nucleosides. *J Phys Chem C* **114**, 7314-7323
478 (2010).
- 479 41 Fisk, H., Westley, C., Turner, N. J. & Goodacre, R. Achieving optimal SERS through
480 enhanced experimental design. *J Raman Spectrosc* **47**, 59-66 (2016).
- 481 42 Leopold, N. & Lendl, B. A New Method for Fast Preparation of Highly Surface-
482 Enhanced Raman Scattering (SERS) Active Silver Colloids at Room Temperature by
483 Reduction of Silver Nitrate with Hydroxylamine Hydrochloride. *J PhysChem B* **107**,
484 5723-5727 (2003).
- 485